BHWM
CYTK icon

Bay Harbor Wealth Management’s Cytokinetics CYTK Stock Holding History

Bay Harbor Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85 Hold
1
– – ﹤0.01% 1238
2026
Q1 		$65 Buy
+1
New +$64 ﹤0.01% 1241

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bay Harbor Wealth Management's CYTK Position: Q2 2026 in Review

Bay Harbor Wealth Management held its Cytokinetics (CYTK) position steady in Q2 2026 at 1 share worth $85. The position accounts for ﹤0.01% of the portfolio, ranked #1238.

Bay Harbor Wealth Management first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Bay Harbor Wealth Management held 1 share of Cytokinetics worth $85 as of Q2 2026.
  • Bay Harbor Wealth Management left its Cytokinetics share count unchanged in Q2 2026.
  • Cytokinetics made up ﹤0.01% of Bay Harbor Wealth Management's portfolio in Q2 2026, its #1238 holding.
  • Bay Harbor Wealth Management first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Bay Harbor Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.